2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Breast
1
Conditions
Pancreatic Neoplasms
9
Peutz-Jeghers Syndrome
3
Exocrine Pancreatic Insufficiency
2
Pancreatic Intraductal Neoplasms
1
Intraductal Papillary Mucinous Neoplasms
1
Hereditary pancreatitis
1
Hereditary Sensory and Autonomic Neuropathies
1
Fanconi Anemia, Complementation Group D1
1
Dysplastic Nevus Syndrome
1
Diabetes Mellitus
1
Colorectal Neoplasms, Hereditary Nonpolyposis
1
Breast Neoplasms
1
Interventions
Fulvestrant
10
Alpelisib
7
Everolimus
6
Cetuximab
6
Letrozole
4
serabelisib
3
ribociclib
3
pembrolizumab
3
palbociclib
3
duvelisib
3
berzosertib
3
Paclitaxel
3
PX-866
3
NVP-BKM120
3
Irinotecan
3
sapanisertib
2
parsaclisib
2
olaparib
2
binimetinib
2
Topotecan
2
Gemcitabine
2
Carboplatin
2
volagidemab
1
venetoclax
1
tivozanib
1
tipifarnib
1
tanezumab
1
talazoparib
1
sotorasib
1
ruxolitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hereditary Sensory and Autonomic Neuropathies
×
Secretin
×
Clear all
NCT02000089
2025-10-09
CAPS5
Johns Hopkins University
Phase 3
Recruiting
9,000 enrolled